ClinicalTrials.gg
CompletedNCT01859078Updated Jun 6, 2017Results posted

A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

A Phase 1 interventional study of Baricitinib and Digoxin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effect of baricitinib on the levels of digoxin in the blood stream and how long it takes the body to remove digoxin. This study will also look at how safe and well-tolerated baricitinib is when given at the same time as digoxin in healthy participants. This study will last approximately 3-4 weeks.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination
  • Women not of
  • Menopausal women
  • Have a of 18.0 to 29.0 kilograms per square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Women who are lactating
  • Have previously completed or withdrawn from this study or any other study investigating baricitinib
  • Currently enrolled in, have completed or discontinued within the last 90 days from a clinical trial involving an product
  • Have a pulse rate less than 50 beats per minute (bpm) at screening
  • Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to Day -1) of a bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • Have an less than 2000 cells/microliter (2×10\^9/liter) at screening or Day -1
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Have been exposed to a within 12 weeks prior to the first dose or expected to need/receive a live vaccine
  • Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study
  • Have used or intend to use any drugs or substances that are known to be substrates, inducers, or inhibitors of P-glycoprotein (P-gp) within 30 days prior to dosing and throughout the study
  • Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Baricitinib + Digoxin

    Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16. Baricitinib - 10 mg administered orally, QD, on Days 8 through 16.

    Drug: Baricitinib · Drug: Digoxin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin

    Time frame: Predose up to 24 hours post-dose on Days 7 and 16

  2. PK: Maximum Concentration (Cmax) of Digoxin

    Time frame: Predose up to 24 hours post-dose on Days 7 and 16

  3. PK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin

    Time frame: Predose up to 24 hours post-dose on Days 7 and 16

Secondary outcomes

  1. PK: Amount of Drug Excreted Unchanged During 1 Dosing Interval (Aeτ) of Digoxin

    Time frame: 0 to 24 hours post-dose on Days 7 and 16

  2. PK: Renal Clearance (CLr) of Digoxin

    CLr is the volume of plasma from which study drug is completely removed by the kidney in a given time and is calculated as Aeτ divided by AUCτ.

    Time frame: Predose to 24 hours post-dose on Days 7 and 16

07

Results

Posted Apr 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneBaricitinib + Digoxin
Started28
Completed28
Not completed0

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin
Time frame:
Predose up to 24 hours post-dose on Days 7 and 16
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin
nanograms*hour/milliliter (ng*h/mL)Digoxin OnlyBaricitinib + Digoxin
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin18.7 ± 1816.8 ± 20
PrimaryPK: Maximum Concentration (Cmax) of Digoxin
Time frame:
Predose up to 24 hours post-dose on Days 7 and 16
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Digoxin
nanograms/milliliter (ng/mL)Digoxin OnlyBaricitinib + Digoxin
PK: Maximum Concentration (Cmax) of Digoxin2.04 ± 231.80 ± 20
PrimaryPK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin
Time frame:
Predose up to 24 hours post-dose on Days 7 and 16
Reported as:
Median · hours (h)
PK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin
hours (h)Digoxin OnlyBaricitinib + Digoxin
PK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin1.00 (0.50 to 2.00)1.00 (0.42 to 2.00)
SecondaryPK: Amount of Drug Excreted Unchanged During 1 Dosing Interval (Aeτ) of Digoxin
Time frame:
0 to 24 hours post-dose on Days 7 and 16
Reported as:
Geometric mean · milligrams (mg)
PK: Amount of Drug Excreted Unchanged During 1 Dosing Interval (Aeτ) of Digoxin
milligrams (mg)Digoxin OnlyBaricitinib + Digoxin
PK: Amount of Drug Excreted Unchanged During 1 Dosing Interval (Aeτ) of Digoxin0.177 ± 180.155 ± 22
SecondaryPK: Renal Clearance (CLr) of Digoxin

CLr is the volume of plasma from which study drug is completely removed by the kidney in a given time and is calculated as Aeτ divided by AUCτ.

Time frame:
Predose to 24 hours post-dose on Days 7 and 16
Reported as:
Geometric mean · Liters/hour (L/h)
PK: Renal Clearance (CLr) of Digoxin
Liters/hour (L/h)Digoxin OnlyBaricitinib + Digoxin
PK: Renal Clearance (CLr) of Digoxin9.46 ± 209.20 ± 18

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Digoxin Only—0/28 (0%)10/28 (35.7%)
Baricitinib + Digoxin—0/28 (0%)6/28 (21.4%)
Most frequent other events
Most frequent other events
EventDigoxin OnlyBaricitinib + Digoxin
HeadacheNervous system disorders5/282/28
DiarrhoeaGastrointestinal disorders1/283/28
PollakiuriaRenal and urinary disorders3/280/28
FatigueGeneral disorders2/281/28

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Baricitinib + Digoxin
Mean33.4 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib + Digoxin
Female0
Male28
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib + Digoxin
Hispanic or Latino0
Not Hispanic or Latino28
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib + Digoxin
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White24
More than one race3
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Baricitinib + Digoxin
United Kingdom28
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2013
First posted
May 21, 2013
Start
May 2013
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01859078
Responsible party
Sponsor
First posted
May 21, 2013
Start date
May 2013
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion